Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07028489 · ClinicalTrials.gov registry record
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
A clinical trial of Non-Small Cell Lung Cancer, sponsored by N-Power Medicine.
- Recruiting
- Registry status
- 130
- Enrollment target
- 6
- Study locations
NCT07028489 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by N-Power Medicine. The registered enrollment target is 130 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT07028489, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by N-Power Medicine.
- RECRUITING
- Registry status
- 130 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
Conditions Studied
Study Locations (6)
Delaware
- Bayhealth Cancer Center- Kent - Dover
- Bayhealth Cancer Center- Sussex - Milford
California
- Pacific Cancer Care - Monterey
Illinois
- Northwest Oncology & Hematology - Elk Grove Village
Pennsylvania
- Lankenau Medical Center - Paoli
Texas
- Oncology Consultants, P.A. - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2029-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07028489
The ClinicalTrials.gov registry entry for NCT07028489 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (80% lower). The listed sponsor is N-Power Medicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07028489 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Delaware, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT07028489 about?
NCT07028489 is a clinical study titled "Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer". The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation o...
What is the current status of trial NCT07028489?
This trial is currently recruiting. The enrollment target is 130 participants. The study started on 2025-06-05. Estimated completion is 2029-04.
What conditions does trial NCT07028489 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
Who is sponsoring clinical trial NCT07028489?
This trial is sponsored by N-Power Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07028489 being conducted?
This trial has 6 study locations across California, Delaware, Illinois, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.